Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H16ClFN4O |
Molecular Weight | 394.829 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=CC2=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)N=CN=C2C=C1
InChI
InChIKey=FBSYJUVNGAMMOK-UHFFFAOYSA-N
InChI=1S/C21H16ClFN4O/c22-18-10-16(5-7-20(18)28-11-13-2-1-3-14(23)8-13)27-21-17-9-15(24)4-6-19(17)25-12-26-21/h1-10,12H,11,24H2,(H,25,26,27)
Molecular Formula | C21H16ClFN4O |
Molecular Weight | 394.829 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:54:30 GMT 2023
by
admin
on
Sat Dec 16 16:54:30 GMT 2023
|
Record UNII |
9XRF7KN4QK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
53630477
Created by
admin on Sat Dec 16 16:54:31 GMT 2023 , Edited by admin on Sat Dec 16 16:54:31 GMT 2023
|
PRIMARY | |||
|
845271-71-8
Created by
admin on Sat Dec 16 16:54:31 GMT 2023 , Edited by admin on Sat Dec 16 16:54:31 GMT 2023
|
PRIMARY | |||
|
9XRF7KN4QK
Created by
admin on Sat Dec 16 16:54:31 GMT 2023 , Edited by admin on Sat Dec 16 16:54:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET->WEAK INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
FECAL; PLASMA; URINE
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
THREE TIMES A DAY |
|
||
Biological Half-life | PHARMACOKINETIC |
|
IN CANCER PATIENTS |
|
||
Tmax | PHARMACOKINETIC |
|
AT DAY 24 |
|
||
Tmax | PHARMACOKINETIC |
|
AT DAY 1 |
|
||